Pharma & drug development

The next generation of antimalarials

Novartis has launched a programme to add novel treatments to its malaria pipeline and to complete clinical trials for two new candidates. So why are new antimalarials needed? Abi Millar finds out.

Over the last two decades, the fight against malaria has been overwhelmingly successful. Between 2000 and 2015, global malaria deaths fell by more than 60%, largely thanks to better vector control, for example via insecticides, and advances in treatment.Unfortunately, the disease remains an enormous healthcare burden, with nearly half the world’s population at risk of infection. In 2016, there were 216 million reported cases of malaria, claiming the lives of 445,000 people. More than two thirds of these malaria deaths (285,000) occurred in children under five.

On top of this, a number of African nations lack the capacity to develop healthcare systems that can deliver appropriate treatment and care.

“A recent study, which pooled data from 33 African countries, estimated that only about a fifth of children with a malaria-induced fever currently receive the right diagnosis and appropriate treatment,” says Dr Harald Nusser, head of Novartis Social Business. “A child dies every two minutes from malaria.”

He points out that, despite the fall in mortality rates, now is not the time for the medical community to lose momentum.

“If we continue to be successful in the fight against malaria, complacency will set in as the number of cases and deaths continues to decrease,” he says. “Global attention will be diverted onto other illnesses, not least noncommunicable diseases, which are rapidly increasing in many African countries.”

Novartis’ investment

Attuned to this threat, Novartis recently announced a renewed commitment to combating the disease. Speaking at the Malaria Summit in London in April, the company said it plans to invest more than $100m in R&D over the next five years. Ultimately, it hopes to develop next-generation antimalarials that could treat the condition in a completely different way.

“The company will also implement an equitable pricing strategy adapted to maximise patient access in malaria-endemic countries when these new treatments become available,” adds Nusser. “It will further help expand access to paediatric antimalarials and implement healthcare system strengthening programmes in four sub-Saharan countries heavily affected by malaria, including Nigeria and the Democratic Republic of the Congo.”

Novartis already has a strong track record in antimalarials. In the early 1990s, the company began to look at underserved areas in global health, giving rise to the Novartis Malaria Initiative.

“In 1994, a joint venture between Novartis and Chinese partners was agreed to develop, test and manufacture an antimalarial treatment – the first collaboration of its kind in Chinese history. This led to the development of the world’s first fixed-dose artemisinin-based combination therapy (ACT),” says Nusser.

Following a landmark agreement with the World Health Organization (WHO) in 2001, Novartis committed to making this ACT available without profit to the public sector of malaria-endemic countries. Although this agreement expired in 2011, the company continues to provide treatments on the same terms.

“So far, more than 850,000 treatments have been distributed without profit,” Nusser explains.

Acts of resistance

As recommended by WHO, ACTs remain the first line of treatment for uncomplicated malaria. Since they combine two active ingredients with different mechanisms of action, they approach the disease from a dual angle, representing a key step up in malaria treatment.

To give some context of their development, the 1980s and 1990s saw the emergence of resistance to earlier therapies (chloroquine and then sulphadoxine-pyrimethamine). This is thought to have contributed to rising malaria mortality throughout the 90s.

“The Institute of Health Metrics and Evaluation at the University of Washington, which provides estimates of malaria deaths, shows mortality increasing from around 746,000 in 1990 to reach a peak of over 990,000 in 2003,” says Nusser. “Many experts believe that this increase in mortality was due to the emergence of treatment resistance, with insecticide resistance also being a strong contributor.”

Since the introduction of ACTs and widespread bed net use, great progress has been made. Unfortunately, history could be set to repeat itself as the pathogens continue to mutate. Cases of ACT-resistant malaria have been seen in the Greater Mekong Region, prompting concerns that it could spread further around Asia and on to Africa.

“In addition, some experts believe that de novo ACT resistance in Africa is also possible. Widespread ACT resistance would have a devastating impact on the global capacity to treat malaria,” says Nusser. “That is why Novartis is working with partners to develop successor treatments so that we will be ready when that day comes.”

This article appears in the August 2018 edition of Pharma Technology Focus 

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: